Reason for request
Inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals in the ‘Central neuropathic pain in adults’ indication extension.
Clinical Benefit
| Substantial |
The actual benefit of LYRICA in the treatment of central neuropathic pain in adults is substantial. |
Clinical Added Value
| no clinical added value |
Lyrica does not provide any improvement in actual benefit (IAB level V) over the usual management of central neuropathic pain in adults. |
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
00PJnp9NaVG85gKj
